HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease.

We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.

Executive Management

Liang Schweizer, PhD
Chief Executive Officer and Chief Scientific Officer
Jeff He, MBA
Chief Operating Officer
Fred Dom, MSc
Chief Financial Officer
Xuqiong (Joanna) Wu, JD, PhD
General Counsel
Francisco Adrian, PhD
Head of Global Disease Biology, Senior Vice President
Nicola Beltraminelli, PhD
Head of Drug Sciences, Vice President
Tracy Smith, MBA
Head of Human Resources, Vice President

Scientific Leaders

He Zhou, PhD
Head of Pharmacology, Executive Director
Stéphanie Beq, PhD
Head of Translational Science, Senior Director
Annabelle Gérard, PhD
Head of External Innovation, Senior Director
Roshan Kumar, PhD
Head of Target Discovery and Collaboration, Director
Andreas Raue, PhD
Head of Data Intelligence, Director
Pascaline Mary, PhD
Head of Antibody Screening Platform, Director
Fernando Bardella, PhD, MBA
Head of IT, Director

Scientific Founders

Andrew Griffiths, PhD

Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI)

David Weitz, PhD

Mallinckrodt Professor of Physics & Applied Physics and Professor of Systems Biology at Harvard University

Bradley Bernstein, MD, PhD

Professor of Pathology at the Massachusetts General Hospital and Harvard Medical School

Jérôme Bibette, PhD

Professor of Soft Matter Physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)

Robert Nicol, PhD

Director of the Technology Labs at the Broad Institute of MIT and Harvard

Open-Innovation Partnerships

We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand single-cell analytics and accelerate commercialization. All of our collaborations are architected for speed and driven by our scientific strategy.

Partnership Highlights

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Read our article in Drug Discovery Today for more information on our open-innovation strategy

Read More